Combined two-stage total pancreatoduodenectomy and esophagectomy for synchronous malignancy of the pancreatic corpus and the esophagus: A surgical case report.
Case report
Esophagectomy
Ivor-Lewis esophagectomy
Synchronous malignancy
Total pancreatectomy
Total pancreatoduodenectomy
Journal
International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
01
03
2023
accepted:
21
03
2023
medline:
27
3
2023
pubmed:
27
3
2023
entrez:
26
3
2023
Statut:
ppublish
Résumé
Synchronous visceral malignancy is rare especially for esophagogastric junction adenocarcinoma combined with malignancy in the pancreas. So far only 7 cases of combined partial pancreatoduodenectomy and esophagectomy for synchronous malignancy have been described in the literature and none for combined total pancreatectomy and esophagectomy. We report the case of a 67-year-old male patient, who underwent multi-modality treatment including two-stage total pancreatoduodenectomy and subsequent Ivor-Lewis esophagectomy for synchronous adenocarcinoma of the distal esophagus and pancreatic multilocal metastases of a renal cell carcinoma after nephrectomy 17 years ago. Pathology revealed R0 resections for both malignancies and there were no postoperative complications. A 12 months follow-up showed no signs of recurrence and a good quality of life. Curative-intent, combined oncological two-stage open total pancreatoduodenectomy and esophagectomy with several days interval is safe and feasible in selected cases when performed by an experienced interdisciplinary team in a high-volume surgical center.
Identifiants
pubmed: 36966719
pii: S2210-2612(23)00156-6
doi: 10.1016/j.ijscr.2023.108028
pmc: PMC10073880
pii:
doi:
Types de publication
Case Reports
Langues
eng
Pagination
108028Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA Netw Open. 2021 Jan 4;4(1):e2021869
pubmed: 33475752
J Med Case Rep. 2013 Sep 10;7:223
pubmed: 24228906
J Am Coll Surg. 2002 Jul;195(1):23-9
pubmed: 12113541
J Surg Oncol. 1995 Dec;60(4):277-81
pubmed: 8551739
JAMA. 2017 Jun 27;317(24):2532-2542
pubmed: 28655021
Acta Chir Belg. 2021 Feb;121(1):46-50
pubmed: 31230557
Ann Surg. 2007 Feb;245(2):187-200
pubmed: 17245171
Surg Today. 2014 May;44(5):967-71
pubmed: 23504004
Surg Today. 1994;24(7):610-5
pubmed: 7949769
J Surg Oncol. 2021 Jan;123(1):204-213
pubmed: 33047324
J Surg Oncol. 1987 Oct;36(2):105-9
pubmed: 3657173
Gan To Kagaku Ryoho. 2013 Nov;40(12):1897-9
pubmed: 24393958
Lancet. 2017 Sep 9;390(10099):1027-1037
pubmed: 28901935
Case Rep Gastrointest Med. 2022 Apr 28;2022:7535036
pubmed: 35529674
Ann Ital Chir. 2014 Oct 07;85(ePub):
pubmed: 25285511
J Pathol. 2013 Nov;231(3):301-10
pubmed: 24308032
Langenbecks Arch Surg. 2009 Mar;394(2):383-5
pubmed: 18704486
Int J Surg. 2018 Dec;60:132-136
pubmed: 30342279
Surg Today. 2000;30(2):168-72
pubmed: 10664342
J Thorac Cardiovasc Surg. 2005 Nov;130(5):1391-8
pubmed: 16256794
J Gastrointest Surg. 2011 Oct;15(10):1893-5
pubmed: 21541769
Ann R Coll Surg Engl. 2011 Sep;93(6):e111-3
pubmed: 21929904
Chirurg. 2000 May;71(5):575-9
pubmed: 10875018
World J Gastroenterol. 2019 Jul 14;25(26):3438-3449
pubmed: 31341367
Patient Saf Surg. 2009 Sep 28;3(1):23
pubmed: 19785744
Mayo Clin Proc. 2000 Jun;75(6):581-5
pubmed: 10852418
N Engl J Med. 2002 Apr 11;346(15):1128-37
pubmed: 11948273
Arch Surg. 2003 Jul;138(7):721-5; discussion 726
pubmed: 12860752
Rozhl Chir. 2015 Jun;94(6):251-5
pubmed: 26174345
Surg Today. 2011 Jun;41(6):745-53
pubmed: 21626317